- Home
- CBZ vs IMTX Comparison
CBZ vs IMTX Comparison
Compare CBZ & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBZ | IMTX |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBZ | IMTX |
|---|---|---|
| Price | $35.07 | $9.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $41.33 | $19.00 |
| AVG Volume (30 Days) | ★ 757.2K | 376.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $922,003,000.00 | N/A |
| Revenue This Year | $3.92 | N/A |
| Revenue Next Year | $4.12 | $25.91 |
| P/E Ratio | $19.19 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $24.29 | $5.05 |
| 52 Week High | $77.91 | $12.41 |
Technical Indicators
Market Signals| Indicator | CBZ | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 49.91 |
| Support Level | $27.84 | $9.61 |
| Resistance Level | $35.68 | $10.64 |
| Average True Range (ATR) | 1.92 | 0.50 |
| MACD | 0.18 | 0.09 |
| Stochastic Oscillator | 91.68 | 70.90 |
Price Performance
Historical ComparisonAbout CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.